Calcineurin activation and scaffolding in A Beta-induced synaptic dysfunction

A Beta 诱导的突触功能障碍中钙调神经磷酸酶的激活和支架

基本信息

批准号：
10312481
负责人：
Olga Prikhodko
金额：
$ 6.64万
依托单位：
UNIVERSITY OF COLORADO DENVER
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-08-11 至 2024-08-10
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10312481
关键词：
A kinase anchoring protein Acute Address Affect Age-Months Alzheimer&apos s Disease Alzheimer&apos s disease model Alzheimer&apos s disease therapy Amyloid beta-42 Amyloid beta-Protein Amyloid beta-Protein Precursor Architecture Behavioral Binding Binding Sites Biological Assay Calcineurin Calcineurin inhibitor Cell membrane Chronic Complex Data Dementia Dendritic Spines Disease Docking Endocytosis Excision Excitatory Synapse Exhibits Exocytosis Exposure to Functional disorder Future Genetically Engineered Mouse Glutamate Receptor Hippocampus (Brain)Immunosuppression Impaired cognition Impairment In Vitro Kidney Knock-in Mouse Lead Learning Long-Term Depression Long-Term Potentiation Measures Mediating Memory Memory impairment Molecular Mus Mutation N-Methyl-D-Aspartate Receptors N-Methylaspartate Nervous system structure Neurodegenerative Disorders Neurofibrillary Tangles Neuronal Plasticity Neurons Organ Pathologic Pathology Pathway interactions Peptides Pharmacology Phosphorylation Play Postsynaptic Membrane Prevalence Prevention Probability Protein Dephosphorylation Protein phosphatase Proteins Radial Regulation Reporting Research Resistance Rodent Model Role Scaffolding Protein Senile Plaques Signal Pathway Signal Transduction Site Specificity Stimulus Synapses Synaptic plasticity Testing Toxic effect Wild Type Mouse Work aging population arm behavioral impairment calcineurin phosphatase conditioned fear cost effective therapy familial Alzheimer disease hippocampal pyramidal neuron in vivo long term memory mouse model mutant neurotransmission new therapeutic target novel novel therapeutic intervention postsynaptic prevent protective effect receptor receptor function scaffold small molecule inhibitor symptom treatment synaptic function tau Proteins therapeutic target water maze

项目摘要

Project Summary Alzheimer’s disease (AD) is the most common form of dementia, with growing prevalence as the aging population continues to grow. Pathologically, this neurodegenerative disease is characterized by amyloid-β (Aβ) plaques and tau tangles. Acute application of Aβ has been shown to inhibit NMDA receptor (NMDAR)- dependent long-term potentiation (LTP, a key form of neuronal plasticity critical for learning and memory), and chronic Aβ exposure caused long-term depression (LTD) and elimination of excitatory synapses. Normal LTD requires the protein phosphatase Calcineurin (CaN) and pharmacological inhibition of CaN prevents Aβ- mediated LTP inhibition and synapse loss in rodent models. However, we not know where in the complex organization and architecture of the nervous system CaN is acting to promote these deleterious impacts of Ab on synaptic function. Here I will test the novel hypothesis that LTP inhibition, excitiatory synapse loss, and impaired cognition associated with mouse models of AD are due to Aβ triggering aberrant postsynaptic CaN activation in hippocampal pyramidal neurons. I will further test whether CaN that is specifically localized to postsynaptic sites by the scaffolding protein AKAP79/150 is responsible for mediating these synaptotoxic effects of Aβ at the molecular, cellular and behavioral levels in an effort to uncover potentially new therapeutic targets.

项目摘要阿尔茨海默氏病（AD）是痴呆症的最常见形式，随着衰老而越来越流行人口继续增长。从病理上讲，这种神经退行性疾病的特征是淀粉样蛋白β （Aβ）斑块和tau缠结。 Aβ的急性应用已显示抑制NMDA受体（NMDAR） - 依赖长期增强（LTP，神经元可塑性的关键形式对于学习和记忆至关重要），并且慢性Aβ暴露导致长期抑郁症（LTD）和消除兴奋性突触。正常有限公司需要蛋白质磷酸蛋白酶钙调蛋白（CAN）和药物抑制CAN可防止Aβ- 啮齿动物模型中介导的LTP抑制和突触损失。但是，我们不知道在综合大楼里哪里神经系统的组织和建筑可以采取行动来促进AB的这些有害影响在突触功能上。在这里，我将测试LTP抑制，令人兴奋的突触丧失和与AD小鼠模型相关的认知受损是由于Aβ触发异常的突触后CAN 海马锥体神经元的激活。我将进一步测试是否可以专门本地化脚手架蛋白AKAP79/150的突触后部位负责介导这些突触毒素 Aβ在分子，细胞和行为水平上的影响，以发现潜在的新疗法目标。